[Acquired hemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with peginterferon α-2a]

MeSH terms

• Antibodies, Monoclonal, Murine-Derived / administration & dosage
• Antibodies, Monoclonal, Murine-Derived / therapeutic use
• Antiviral Agents / adverse effects*
• Antiviral Agents / therapeutic use
• Autoantibodies / blood
• Autoantibodies / immunology
• Autoantigens / immunology
• Cyclophosphamide / administration & dosage
• Cyclophosphamide / therapeutic use
• Factor VIII / immunology
• Glucocorticoids / administration & dosage
• Glucocorticoids / therapeutic use
• Hematoma / etiology
• Hemophilia A / chemically induced*
• Hemophilia A / drug therapy
• Hemophilia A / immunology
• Hepatitis C, Chronic / complications
• Hepatitis C, Chronic / drug therapy*
• Humans
• Immunosuppressive Agents / therapeutic use
• Interferon-alpha / adverse effects*
• Interferon-alpha / therapeutic use
• Male
• Middle Aged
• Polyethylene Glycols / adverse effects*
• Polyethylene Glycols / therapeutic use
• Recombinant Proteins / adverse effects
• Recombinant Proteins / therapeutic use
• Ribavirin / therapeutic use
• Rituximab